Article information
Full text is only available in PDF
Biblografía
[1.]
R. De Górgolas, Torres, C. Verdejo, et al.
Infestación por Fasciola hepatica. Biopatología y nuevos aspectos diagnósticos y terapéuticos.
Enf Infecc Microbiol Clin, 10 (1992), pp. 514-519
[2.]
M. Almendras, J. Rivera, J. Seijas, K. Almendras.
Hepatic fasciolasis in children, uncommon clinical manifestations.
Arq Gastroenterol, 34 (1997), pp. 241-247
[3.]
J. Merino, M.J. Amérigo, L. Álvarez, I. Erdozain.
Fasciolasis humana con presentación atípica y grave. Tratamiento con triclabendazol.
Enf Infecc Microbiol Clin, 16 (1998), pp. 28-30
[4.]
W. Apt, X. Aguilera, F. Vega, C. Miranda, I. Zulanlay, C. Perez, et al.
Treatment of human chronic fasciolasis with triclabendazole: Drug efficacy and serologic response.
Am J Trop Hyg, 52 (1995), pp. 532-535
[5.]
S. Picot, M. Querrec, J.L. Ghez, A. Goullier-Fleuret, R. Grillot, P. Ambroise-Thomas.
A new report of Triclabendazole efficacy during invading phase fasciolasis.
Europ J Clin Microbiol, 11 (1992), pp. 269-270
[6.]
U. Bechtel, H.E. Feucht, E. Held, T. Vogl, H.D. Nothdurft.
Infection with fasciola hepatica in a family: Diagnosis and treatment.
Dtsch Med Wschr, 117 (1992), pp. 978-982
[7.]
M.L. García, J.M. Marugán de Miguelsanz, M.J. Ordóñez, S. Costilla, N. Díez.
Fasciolasis hepática: Un nuevo caso en la infancia.
An Esp Pediatr, 50 (1999), pp. 65-67
[8.]
L. Loutan, M. Bouvier, B. Rojanawisut, H. Stalder, M.C. Rouan, G. Buescher, et al.
Single treatment of invasive fasciolasis with Triclabendazole.
Lancet, 2 (1989), pp. 383
[9.]
J.B. Lecaillon, J. Godbillon, J. Campestrini, C. Naquira, L. Miranda, R. Pacheco, et al.
Effect of food on the bioavailability of Triclabendazole in patients with fasciolasis.
Br J Clin Pharmacol, 45 (1998), pp. 601-604
Copyright © 2002. Asociación Española de Pediatría
